Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Stefano Cascinu, University of Modena, Modena, Italy, gives an update on the GAP trial (NCT02043730), a GISCAD Phase II comparative randomized trial of nab-paclitaxel plus gemcitabine in locally advanced, unresectable pancreatic cancer (LAUPC). This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.